Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 1999

View Archived Issues

COX-2 inhibitors can potentially be used safely in patients with decompensated cirrhosis

PEG-conjugated prodrugs of anticancer compounds in development at Enzon

Schwarz acquires Spanish firm

Wide series of cytokine production inhibitors reported by JT

Phenoxypyridine inhibitors of Na+/Ca2+ exchange from Taisho

HPV-33 DNA fragments useful in diagnosis of HPV and cervical carcinoma

Hericenal C: new enzyme inhibitor for diabetes mellitus

FDA approves amprenavir, first new protease inhibitor in more than two years

SBIR grant to CoCensys for analgesic discovery

Potent, orally bioavailable NK3 antagonist under study at Warner-Lambert

T-2585.HCl: a novel, potent and selective PDE4 inhibitor with potential as asthma Rx

Furosemide prevents sound-induced seizures in rat model

Immune Response describes herpes vaccine research at FASEB 99

CGP-57148B useful for overcoming resistance to etoposide- and daunorubicin-induced apoptosis

Phosphodiesterase inhibition contributes to the antiinflammatory activity of darbufelone

SciClone and Sigma-Tau sign Zadaxin partnership

News from FASEB: serine protease inhibitor prevents reperfusion injury in preclinical model

Resistance profile of novel apoptosis inducer characterized in preliminary studies

CD-437: new apoptogenic retinoid examined for resistance using leukemia cells

Preclinical and early clinical data reported for DX-8951f at AACR meeting

CardioRex versus probucol in atherosclerosis model

Bay-y-5959 is not associated with proarrhythmic activity in dogs with CHF

NX-211 compared to free lurtotecan regarding pharmacokinetics, toxicity and efficacy

News from FASEB: ETA antagonist with potential in the treatment of pulmonary hypertension

European Commission approves novel albumin-free treatment for hemophilia A

News from AACR: 9-NC does not require conversion to 9-AC to exert antitumor activity

News from FASEB: dermal pharmacology of Dekk-Tec's A-007

Immunological response to GMK melanoma vaccine examined as part of phase III trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...